The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
AABB Publishes New Biotherapies Manual
September 18, 2026
FDA Approves Gene Therapy for Pediatric Patients With Sanfilippo Syndrome Type A
September 18, 2026
NHLBI, University of the West Indies to Host Sickle Cell in Focus 2026
September 16, 2026